Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallelgroup trial (the CONFIDENCE study)
Abstract
Aim. Progressive β -cell dysfunction hinders the maintenance of glycaemic control in type 2 diabetes, but comparative data on β -cell-protective therapies are lacking in the early stage of type 2 diabetes. Here we evaluated the comparative glycaemic efficacy and
Diabetes, fasting glucose, and the risk of glaucoma. A Meta-analysis
Abstract
We performed a systematic review to summarize the association of diabetes and blood glucose levels with glaucoma, intraocular pressure (IOP), and ocular hypertension in the general population. Clinical Relevance. Diabetes has been proposed as a risk factor for glaucoma, but
TECOS – the new study of cardiovascular safety of DPP-4 inhibitors
Abstract
The paper is presented the detailed review of TECOS Study – the third long-term RCS, devoted to the assessment of the cardiovascular safety of sitagliptin (first and the most studied representative of the DPP4 inhibitors). The TECOS Study confirmed of the
An effective strategy for the treatment of obesity
Abstract
Actuality . The methods of pharmacotherapy of obesity is constantly being improved. Objective. To study the eating behavior of obese patients, the use of Reduksin® (Sibutramine + MCC) and Reduksin ® in combination with metformin in obese women. Material and methods
The first prandial agonist of GLP-1 receptors: the efficiency and safety ot its using in clinical practice
Abstract
The paper discusses the prandial effects of the prandial GLP-1 receptor agonist exenatide: as a result of the effective elimination of the prandial hyperglycemia and the glycemia variability, reduction of the hypoglycemia risk without the weight gain. It was the advantage of
ABCD rules and vildagliptin: current approaches in type 2 diabetes management
Abstract
Type 2 Diabetes (T2DM) is a progressive disease characterized by deterioration of glycaemia and escalating therapeutic complexity. Recent intervention trials have underscored problems surrounding the risk-benefit balance of most therapeutic strategies in T2DM given,
Regenerative medicine in diabetes
Abstract
Diabetes is a common multisystem disease that results in hyperglycemia due to a relative or absolute insulin deficiency. Improved glycemic control decreases the risk of development and progression of microvascular and, to a lesser extent, macrovascular complications and
Diabetes and heart – myocardial damage in diabetic cardiomyopathy
Abstract
The mechanism of myocardial damage in diabetes is considered. The myocardial injury in diabetic cardiomyopathy, is described in details. Changes on molecular, tissue, organ level is described.
Dual mechanism of action of canagliflozin: excretion of glucose into the urine it is just the beginning of the story
Abstract
Canagliflozin is a highly selective inhibitor of the sodium dependent glucose co-transporter type 2 (SGLT2). SGLT2 inhibitors act to lower plasma glucose by lowering reabsorbtion of glucose filtered by the kidney. Canagliflozin is also a low potency SGLT1 inhibitor. Sodium
Diabetic foot syndrome: integrated treatment of trophic neuropathic ulcers
Abstract
Diabetic foot is one of the serious complications of diabetes mellitus, causing one of the main causes of morbidity and mortality, due to the rapid formation and a long healing of wound defects of the skin and soft tissues often leading to the lower limb amputations.
Focus – woman with the metabolic syndrome: newer evidences correctability
Abstract
There has been continuing growth in the number of patients with various manifestations of the metabolic syndrome. Currently, the prevalence of MS is 20–40% of the population. Constantly improving approaches to the early detection of MS and ways of correction of its